News Archive

A Maryland-based biotechnology firm seems to have solved a puzzling issue for drug targeting and delivery that may usher in an era of gene therapies for neurological disorders. Rockville, Maryland’s REGENXBIO’s NAV Technology Platform provides the ability to treat neurological disorders by targeting specific disease-related genes or gene products. Their patented technology glides across the blood-brain barrier (BBB) without triggering the patient’s immune system as with unengineered adeno-associated virus (AAV)-derived vectors, providing localized gene delivery with few side effects.

Image: https://biobuzz.io

In May of 2018 Kite Pharma, a Gilead Company, announced the opening of a new Neo Antigen Facility in Gaithersburg, MD. Less than one year later in April of 2019, the company, announced that it was building a new biomanufacturing facility on a 20-acre site in Frederick, MD. Since then, Kite has been diligently working to build a world-class leadership team at both sites to achieve an important mission.

Image: https://biobuzz.io

EMMes has announced the development of a vaccine for the flu that is “universal influenza vaccine”.  EMMes is the part of a team including medical centers, private industry, and universities that support the development of a vaccine. The vaccine provides protection for a long time as compared to currently available vaccines. Moreover, it is capable to fight against a wide range and variety of influenza. The news was announced in ROCKVILLE on Dec 2, 2019.

Image: https://askhealthnews.com

Full-house, standing room only at our ‘Launching Life Sciences Innovation in Baltimore’ event co-hosted by LifeBridge Health and The LaunchPort at Rye Street Tavern. Thank you to MARYLAND BUSINESS INCUBATION ASSOCIATION and Weller Development for your support.

Image: https://www.linkedin.com

This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Dental and Craniofacial Research (NIDCR) on behalf of the NIH.

A biotech startup that’s backed by Silicon Valley’s well-known Y Combinator accelerator has ties to Baltimore: GEn1E Lifesciences is working to commercialize a treatment for inflammatory and age-related diseases that was developed at the University of Maryland, Baltimore, and is partnering with a Baltimore-based startup that also grew out of UMB collaboration.

Image: Dr. Ritu Lal is CEO of GEn1E Lifesciences. (Courtesy photo)

We’re bringing together neurotech companies, academic researchers and federal labs to network and collaborate.

Image: https://www.eventbrite.com

Montgomery County has a new top economic development official: Benjamin Wu, formerly a top adviser to Maryland Gov. Larry Hogan.

Wu will take over as the president and CEO of the Montgomery County Economic Development Corporation Dec. 18, according to a news release. The group has been searching for a new leader ever since David Petr, its inaugural CEO, left this fall.

Image: Benjamin Wu will take over as the new head of the Montgomery County Economic Development Corporation. DBED

GERMANTOWN, Md. – Sept. 10, 2019 – PRLog — Primetime Life Sciences, LLC,  a Maryland based pharmaceutical company focused on discovery and development of new and smart treatments, announced today that the company has successfully met the Phase I grant milestones, and has been awarded Phase II funding of $2.63 million from a Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH). The SBIR program supports scientific excellence and technological innovation by encouraging small businesses to engage in translation research and bring innovative treatments.

Alex Trebek appeared well en route to surviving pancreatic cancer this past summer when his doctors followed up his initial successful chemotherapy with an undisclosed immunotherapy. That move backfired.

“I was doing so well. And my numbers went down to the equivalent of a normal human being who does not have pancreatic cancer. So we were all very optimistic. And they said, ‘Good, we’re gonna stop chemo, we’ll start you on immunotherapy,” Trebek said September 17 on ABC’s Good Morning America. “I lost about 12 pounds in a week. And my numbers went sky-high, much higher than they were when I was first diagnosed.”